At the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers presented new data on the use of a pioneering drug technology known as "antibody-targeted chemotherapy" to fight acute myelogenous leukemia (AML), a virulent and often fatal form of cancer...
Original Article: Antibody-Targeted Chemotherapy Fights AML With Fewer Side Effects